What Is a 510(k)? FDA Clearance Explained for MedTech Teams

2026-09-26 · Caduvo Team

A complete guide to the FDA 510(k) premarket notification pathway: substantial equivalence, eSTAR requirements, review timelines, fees, and clearance rules.

Medical device founders often say their product is "FDA approved" when it is actually cleared. The distinction is not semantic. It dictates your regulatory pathway, bench testing requirements, and clinical evidence strategy. The Premarket Notification, universally referred to as a 510(k), serves as the primary regulatory gateway the Food and Drug Administration uses to review moderate-risk medical hardware and software entering the United States commercial market.

Understanding what is a 510k requires understanding comparative review. Rather than establishing safety and effectiveness entirely through standalone premarket clinical trials, a 510(k) demonstrates that a device performs as safely and effectively as an existing legally marketed benchmark. Knowing how the agency evaluates these submissions keeps your team from misallocating capital on misaligned testing protocols or misinterpreting statutory review requirements.

Who Needs a 510(k) and Who Does Not

The FDA regulates medical devices under a risk-based framework established by Congress in the Medical Device Amendments of 1976, which were incorporated into the Federal Food, Drug, and Cosmetic Act (FD&C Act). According to FDA device classification data, devices fall into three distinct classes based on the degree of control necessary to assure safety and effectiveness:

Under 21 CFR Part 807 Subpart E, a manufacturer must file a 510k submission when introducing a device to the U.S. market for the first time. Section 510(k) of the FD&C Act requires entities to notify the FDA of their intent to market at least 90 days in advance. A new submission is also required when reintroducing a device that undergoes significant modifications in design, materials, chemical composition, energy source, manufacturing process, or indications for use that could affect its safety or effectiveness.

Certain commercial arrangements modify these obligations. Under 21 CFR 801.1(c), distributors do not submit a 510(k) for an existing product they distribute under their own label. The label must include phrasing such as "Distributed by ABC Company" or "Manufactured for ABC Company," while complaint handling remains governed by 21 CFR 820.198. As outlined in FDA 510(k) guidance, a new company that does not manufacture any medical devices should not register its facility until it is within 30 days of manufacturing and distributing the device. The initial 510(k) filing must state that the company is not currently registered.

Substantial Equivalence: Cleared vs. Approved

The statutory standard for obtaining a 510(k) clearance is establishing substantial equivalence (SE). Under section 513(i)(1)(A) of the FD&C Act, a 510(k) is a premarket notification made to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device. Submitters must compare their device to one or more similar legally marketed devices and support their substantial equivalence claims with objective data.

A legally marketed predicate device can be a preamendments device legally marketed prior to May 28, 1976, a device cleared through the 510(k) pathway, a product originally on the market as a Class III device that was downclassified to Class II or Class I, or a 510(k) exempt device. According to FDA predicate device criteria, almost all modern submissions compare their candidate to a postamendments device recently cleared under 510(k). The predicate must be legally marketed, meaning it cannot violate the FD&C Act, though an applicant may cite a predicate that is no longer actively marketed in the U.S.

A claim of substantial equivalence does not mean the devices must be identical. As established by FDA guidance, substantial equivalence is evaluated across intended use, design, energy used or delivered, materials, performance, safety, effectiveness, labeling, biocompatibility, standards, and other applicable characteristics. When differences exist between the candidate device and the predicate, the manufacturer must provide scientific performance testing demonstrating that these differences do not diminish safety or effectiveness.

This comparative mechanism explains why 510(k) devices are "cleared" rather than "approved." The FDA issues an order in the form of a letter clearing the device for commercial distribution once substantial equivalence is established. Marketing a 510(k) device as "FDA approved" misrepresents its regulatory status under federal law, as approval is reserved for Class III PMA submissions. If a novel moderate-risk device has no valid predicate, the 510(k) route cannot be used, requiring the team to evaluate the De Novo classification pathway.

Structure of an eSTAR 510(k) Submission

Premarket notifications have transitioned away from disparate paper files and standalone PDF assemblies. On October 3, 2022, the FDA introduced electronic uploads through the CDRH Customer Collaboration Portal. Effective October 1, 2023, all non-exempt 510(k) submissions must be submitted as electronic submissions using the electronic Submission Template And Resource (eSTAR) format.

The eSTAR framework structures technical documentation to address the elements defined in 21 CFR 807 Subpart E. A complete filing includes:

Clinical trials are rarely needed for standard premarket notifications. Per FDA premarket review criteria, only a small percentage of 510(k) submissions require clinical data. When analytical bench data or animal models cannot prove equivalence for technological characteristics, the sponsor must conduct human clinical testing under an Investigational Device Exemption (IDE).

Timelines, Fees, and Common Review Deficiencies

Section 510(k) of the FD&C Act requires submitters to notify the agency at least 90 days in advance of introducing a device into commercial distribution. The FDA charges a fee for reviewing Premarket Notifications. Filings submitted through the CDRH Portal undergo an initial intake review to confirm completeness under the agency's Refuse to Accept (RTA) policy.

During substantive review, the FDA may issue an Additional Information (AI) request if the documentation does not fully demonstrate substantial equivalence. Reviewers examine specific technical areas where deficiencies commonly arise:

Regulatory planning must occur alongside commercial access planning. Securing 510(k) clearance allows legal marketing, but it does not guarantee payer reimbursement. Teams can evaluate existing CPT and HCPCS codes, payer coverage determinations, and predicate reimbursement precedent through platforms like Caduvo early in product development so that cleared indications support commercial adoption.

Actionable 510(k) Milestones for Device Founders

To keep your clearance pathway on schedule, execute these operational steps:

Sources

  1. Premarket Notification 510(k) | FDA
  2. Medical Device Safety and the 510(k) Clearance Process | FDA
  3. 510(k) Clearances | FDA
  4. Learn if a Medical Device Has Been Cleared by FDA for Marketing | FDA
  5. How to Find and Effectively Use Predicate Devices | FDA
  6. 510(k) Frequently Asked Questions | FDA

General information, not regulatory, legal or reimbursement advice. Company and product names belong to their owners; a mention does not imply affiliation or endorsement. Report an error. Data and corrections policy.

Related reading